LSV Asset Management
PCRX icon

LSV Asset Management’s Pacira BioSciences PCRX Stock Holding History

LSV Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Buy
517,100
+197,300
+62% +$4.38M 0.03% 380
2025
Q4 		$8.28M Buy
319,800
+205,500
+180% +$4.89M 0.02% 420
2025
Q3 		$2.95M Buy
114,300
+19,100
+20% +$469K 0.01% 533
2025
Q2 		$2.27M Buy
95,200
+13,100
+16% +$330K 0.01% 539
2025
Q1 		$2.04M Buy
82,100
+64,800
+375% +$1.55M ﹤0.01% 562
2024
Q4 		$326K Sell
17,300
-12,600
-42% -$221K ﹤0.01% 717
2024
Q3 		$450K Buy
29,900
+13,767
+85% +$235K ﹤0.01% 712
2024
Q2 		$462K Buy
+16,133
New +$459K ﹤0.01% 735

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return